|
|
|
 Related Articles
|
|
|
|
| |
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced that new data from a large European clinical trial, published Friday in The Lancet, shows that AVANT's partner, GlaxoSmithKline's, Rotarix® rotavirus vaccine to be effective against the five most commonly circulating rotavirus types (G1, G2, G3, G4 ad G9). These virus types are responsible for more than 98% of rotavirus gastroenteritis (RVGE) disease in Europe during the first two years of life2. [click link for full article] (Source: Immune System / Vaccines News From Medical News Today) |
| |
|
| |
| |
CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities. The results from the Phase III, double blind, placebo-controlled trial I.M.P.A.C.T. [click link for full article] (Source: Immune System / Vaccines News From Medical News Today) |
| |
|
| |
| |
New data from a large European clinical vaccine trial, published in The Lancet, shows Rotarix™, GSK's rotavirus vaccine, to be effective against the five most commonly circulating rotavirus types (G1, G2, G3, G4 and G9).These virus types are responsible for more than 98% of rotavirus gastroenteritis (RVGE) disease in Europe during the first two years of life2. [click link for full article] (Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today) |
| |
|
| |
| |
As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial. The lead investor in the company, MIG-Fonds, is extremely satisfied with the expanding patent portfolio of Affiris GmbH. (Source: News-Medical News Feed) |
| |
|
| |
| |
The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9). (Source: News-Medical News Feed) |
| |
|
| |
| |
The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results. [click link for full article] (Source: Immune System / Vaccines News From Medical News Today) |
| |
|
| |
| |
Researchers told an open scientific meeting in Seattle, Washington, on Monday, November 6th, that a clinical trial on Merck's prototype HIV vaccine V520 had been halted because interim results suggested there was an apparent increased risk of becoming infected with HIV in the vaccine group compared with the placebo group. [click link for full article] (Source: Health News from Medical News Today) |
| |
|
| |
| |
The new analyses revealed from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results. [click link for full article] (Source: Immune System / Vaccines News From Medical News Today) |
| |
|
| |
| |
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that it has initiated Phase II testing of its cell culture-based seasonal influenza vaccine in the U.S. The initiation of Phase I was announced on Sept 25, 2006. This project is part of a contract awarded in 2005 by the U.S. Department of Health and Human Services (HHS) aimed at accelerating the development of a new cell culture- based influenza vaccine. [click link for full article] (Source: Asthma / Respiratory News From Medical News Today) |
| |
|
| |
| |
St. Jude Medical, Inc. (NYSE:STJ) announced that the Resynchronization Therapy In Normal QRS (RethinQ) Trial, which studied a subgroup of heart failure patients, most of whom are currently not indicated for cardiac resynchronization therapy (CRT), did not reach its primary effectiveness endpoint of improved oxygen consumption at peak exercise (peak VO2). [click link for full article] |
| |
|
| |
|
|
Related Companies |
| |
|
|
|